1-4 of 4
F. Ravandi
Close
Sort by
Journal Articles

Hypomethylation Therapy of Decitabine in Patients with Myelodysplastic Syndromes (MDS) Induces Apoptosis and Reduces Proliferation.

I. Jilani, H. Kantarjian, M. Gorre, J.-P. Issa, J. Bennett, A. Raza, F. Ravandi, H. Saba, M. Albitar
Journal: Blood
Blood (2005) 106 (11): 371.
https://doi.org/10.1182/blood.V106.11.371.371
Published: 2005
Journal Articles

Weighted Prognostic Models for Survival in Untreated and Previously Treated Patients with CLL.

William G. Wierda, MD, PhD, S. OBrien, MD, X. Wang, MS, A. Ferrajoli, MD, S. Faderl, MD, D. Thomas, MD, F. Ravandi, MD, K. Do, PhD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MD
Journal: Blood
Blood (2005) 106 (11): 5012.
https://doi.org/10.1182/blood.V106.11.5012.5012
Published: 2005
Journal Articles

Serum Beta-2 Microglobulin: The Universal Independent Prognostic Factor for Patients with CLL.

William G. Wierda, MD, PhD, X. Wang, MS, S. OBrien, MD, S. Faderl, MD, A. Ferrajoli, MD, D. Thomas, MD, F. Ravandi, MD, J. Cortes, MD, F. Giles, MD, C. Koller, MD, H. Kantarjian, MD, S. Lerner, MS, M. Keating, MB BS
Journal: Blood
Blood (2005) 106 (11): 5018.
https://doi.org/10.1182/blood.V106.11.5018.5018
Published: 2005
Journal Articles

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

William G. Wierda, MD, PhD, S. OBrien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, F. Giles, MD, J. Cortes, MD, D. Thomas, MD, F. Ravandi, MD, G. Garcia-Manero, MD, M. Andreeff, MD, S. Lerner, MS, H. Kantarjian, MD, M. Keating, MD
Journal: Blood
Blood (2005) 106 (11): 719.
https://doi.org/10.1182/blood.V106.11.719.719
Published: 2005